{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-302201","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.113409+00:00","generated_at":"2026-06-21T06:15:33.623386+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Arcellx and Kite Pharma enter CAR T-cell therapy collaboration; $225M upfront + $100M equity","bullets":["Collaboration and License Agreement with Kite Pharma (Gilead) for CART-ddBCMA, a CAR T therapy for myeloma.","Arcellx receives $225M upfront cash payment and $100M equity investment from Kite.","Eligible for milestones up to $635M per NextGen Product and $508M per Non-Auto Product.","Arcellx retains co-development/co-commercialization option and royalties on Licensed Products.","Deal subject to HSR review and other regulatory approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-302201","json":"https://secwatch.observer/filing/0001193125-22-302201.json","markdown":"https://secwatch.observer/filing/0001193125-22-302201.md","text":"https://secwatch.observer/filing/0001193125-22-302201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522302201/0001193125-22-302201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522302201/d378409d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:15:33.623386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}